RNXT logo

RENOVORX INC

RNXTNASDAQ
๐Ÿ† #4220 by market capEarnings Mar 29US Equity
$0.94โ–ผ $0.11 (โˆ’10.29%)
Market closed ยท at close
๐Ÿ””
Track RNXT
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 10.3%
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$43M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
โ€”
๐Ÿ“ŠGross Margin
84.4%
High
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
23.0x
Expensive
Otter Score
โ€”
Insufficient data
No chart data available for RNXT.

Trading Snapshot

Day Range
$0.94 โ€“ $1.03
52-Week Range
$0.73 โ€“ $2.59
Volume (shares)
477,430
Avg Volume (shares)
โ€”
Shares Outstanding
45.1M
Next Earnings
2027-03-29

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$1M
P/E Ratio
โ€”
P/S Ratio
23.0x
EPS (TTM)
$-0.31
Dividend Yield
โ€”
Dilution (1yr)
+58.6%
RNXT logo

RENOVORX INC

RNXT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1Mโ–ฒ +2511.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
70.9%โ–ผ โˆ’29.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
โˆ’$13Mโ–ฒ +14.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
โˆ’$11Mโ–ฒ +20.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
35.3Mโ–ฒ +58.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7Mโ–ผ โˆ’$64K YoY
StockOtter ยท stockotter.space

About RENOVORX INC

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWireยท3d ago

RenovoRx Appoints Interventional Oncology Medtech Leader Richard Stark to its Board of Directors

MOUNTAIN VIEW, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (โ€œRenovoRxโ€ or โ€œthe Companyโ€) (Nasdaq: RNXT), a life sciences company commercializing RenovoCath ยฎ , a patented, FDA-cleared drug-delivery device, a

MarketBeatยท16d ago

RenovoRx Q3 Earnings Call Highlights

RenovoRx NASDAQ: RNXT reported record third-quarter 2026 revenue of $1.07 million, exceeding $1 million in quarterly sales for the first time as more cancer centers adopted its RenovoCath drug-delivery device.

Seeking Alphaยท16d ago

RenovoRx, Inc. (RNXT) Q3 2026 Earnings Call Transcript

RenovoRx, Inc. (RNXT) Q3 2026 Earnings Call Transcript

Zacks Investment Researchยท16d ago

RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates

RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year ago.

GlobeNewsWireยท17d ago

RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million

Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel Grows to More Than 65 Centers Maintains 2026 Annual Revenue Guidance of $3.75M to $4.25M First Physician-Driven Expansion Using TAMP B

GlobeNewsWireยท25d ago

RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum

MOUNTAIN VIEW, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ย (โ€œRenovoRxโ€ or โ€œthe Companyโ€) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoC